Every Form 4 that OnKure Therapeutics (OKUR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OKUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OKUR filings page.
OnKure Therapeutics, Inc. director Isaac Manke filed an amended ownership report reflecting a stock option holding rather than a transaction. The amendment states that a previously reported disposition and corresponding acquisition of an option to purchase 15,300 shares of Class A Common Stock in connection with an Option Repricing did not occur. The filing instead reports a stock option, exercisable at $18.20 per share, covering 15,300 underlying shares and expiring on October 3, 2034. According to the vesting schedule, 1/36 of the option vested on November 4, 2024 and 1/36 continues to vest monthly, contingent on continued service.
OnKure Therapeutics, Inc. reported that director Edward T. Mathers received a grant of 22,350 stock options on August 7, 2026. The options carry an exercise price of $4.14 per share and are exercisable for Class A Common Stock. All of the shares subject to the option vest on the earlier of June 4, 2027 or the day prior to the company's next annual meeting of stockholders, subject to his continued service, and expire on August 6, 2036. Following this grant, he holds 22,350 derivative securities of this type directly.
OnKure Therapeutics, Inc. reported that director Liam Ratcliffe received a grant of 22,350 stock options, each representing the right to buy one share of Class A Common Stock at an exercise price of $4.14 per share. All 22,350 options will vest on the earlier of June 4, 2027 or the day prior to the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, Ratcliffe holds 22,350 derivative securities of this option award, which is scheduled to expire on August 6, 2036.
OnKure Therapeutics, Inc. director Andrew John Phillips received a grant of stock options covering 22,350 shares of Class A common stock at an exercise price of $4.14 per share. The options expire on August 6, 2036 and vest 100% on the earlier of June 4, 2027 or the day prior to the company’s next annual meeting of stockholders, contingent on his continued service. Following this award, he holds options on 22,350 shares.
OnKure Therapeutics director Isaac Manke reported equity compensation and option repricing activity involving stock options for Class A Common Stock. On August 7, 2026 he received a grant of 300,000 stock options with an exercise price of $4.14 per share, expiring on August 6, 2036. One quarter of these options vests on February 24, 2027 and the remainder vests in equal monthly installments over the following 36 months, contingent on continued service. On the same date, 15,300 options with an original exercise price of $18.20 per share expiring October 3, 2034 were returned to the issuer and replaced with 15,300 repriced options at an exercise price of $4.14, with the same vesting and expiration. Under the company’s one-time Option Repricing program, if any repriced option is exercised before the end of a defined retention period, the holder must pay the original higher exercise price instead of $4.14.
OnKure Therapeutics, Inc. reported that director Valerie Malyvanh Jansen received a grant of a stock option covering 22,350 shares of Class A common stock. The option has an exercise price of $4.14 per share and expires on August 6, 2036. According to the terms, 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to OnKure’s next annual meeting of stockholders, conditioned on her continued service as a provider through the applicable vesting date. Following this award, she holds 22,350 stock options directly.
OnKure Therapeutics director Michael G. Grey received a grant of 22,350 stock options to purchase Class A common stock at an exercise price of $4.14 per share. All options vest on the earlier of June 4, 2027 or the day before the next annual stockholder meeting, subject to continued service, and expire on August 6, 2036. Following this grant, he holds 22,350 options directly.
OnKure Therapeutics, Inc. reported that director R Michael Carruthers received a grant of stock options covering 22,350 shares of Class A common stock on August 7, 2026. The options have an exercise price of $4.14 per share, expire on August 6, 2036, and will vest 100% on the earlier of June 4, 2027 or the day prior to the company’s next annual meeting of stockholders, subject to continued service.
OnKure Therapeutics, Inc. reported that President and CEO Nicholas A. Saccomano received a grant of stock options for 150,000 shares of Class A Common Stock on August 7, 2026, with an exercise price of $4.14 per share and vesting in equal monthly installments over 48 months starting September 7, 2026, subject to continued service.
The company also implemented a one-time stock option repricing effective August 7, 2026 for options with exercise prices of at least $10.00 per share. Several of the CEO’s existing options with exercise prices of $21.20, $13.99, and $18.20 per share were reported as dispositions to the issuer and regrants at an amended exercise price of $4.14 per share. Footnotes state that there was no change to the vesting schedules, expiration dates, or number of shares underlying the repriced options, and that a "Retention Period" runs from August 7, 2026 until the earlier of February 7, 2028 or a Change in Control, during which early exercise of repriced options requires payment of the original higher exercise price.
OnKure Therapeutics, Inc. reported that Chief Financial Officer Jason A. Leverone received a new option grant for 50,000 shares of Class A common stock at an exercise price of $4.14 per share, expiring in 2036. He also participated in a one-time option repricing, with previously granted options for 5,781, 5,322, and 130,611 shares surrendered to the issuer and concurrently regranted with a reduced exercise price of $4.14 per share, while maintaining the same vesting schedules, expiration dates, and number of underlying shares. Footnotes state that repriced options require paying the original higher exercise price if exercised before the end of a defined Retention Period.
OnKure Therapeutics, Inc. reported equity compensation changes for Chief Scientific Officer Dylan Hartley involving stock options on Class A Common Stock. Hartley received a new grant of 50,000 employee stock options with an exercise price of $4.14 per share, expiring on August 6, 2036; 1/48 of these options vest on September 7, 2026 and monthly thereafter, conditioned on continued service. In addition, a one-time Option Repricing effective August 7, 2026 applied to options with exercise prices at or above $10.00 held by continuing employees and certain service providers. In connection with this repricing, 137,603 options with a prior exercise price of $18.20 were reported as disposed to the issuer and a corresponding 137,603 options were granted back to Hartley with a revised exercise price of $4.14 per share, keeping the original vesting schedule (1/4 vested on June 9, 2025 and 1/48 vesting monthly thereafter), expiration date of October 3, 2034, and number of underlying shares unchanged. During a defined Retention Period starting August 7, 2026 and ending on the earlier of February 7, 2028 or a Change in Control, any early exercise of these repriced options requires paying the original higher exercise price rather than the reduced $4.14.
OnKure Therapeutics, Inc. reported multiple stock option adjustments for Chief Medical Officer Samuel Agresta effective August 7, 2026. The company implemented a one-time Option Repricing for employee options with exercise prices at or above $10.00 per share, resetting the exercise price of affected options, including Mr. Agresta’s, to $4.14 per share, the closing price of the Class A Common Stock on the effective date. There was no change to vesting schedules, expiration dates or the number of underlying shares. A Retention Period applies: if a repriced option is exercised before the earlier of February 7, 2028 or a Change in Control, the holder must pay the original, higher exercise price; otherwise the reduced $4.14 exercise price applies.
OnKure Therapeutics President and CEO Nicholas A. Saccomano reported a small automatic share sale tied to equity compensation. He sold 86 shares of Class A Common Stock on June 22, 2026 at a weighted average price of $4.3963 per share to cover tax withholding obligations from vested restricted stock units under the 2023 RSU Equity Incentive Plan. Following this tax-related sale, he holds 11,247 shares directly, including 4,000 shares acquired through the company’s 2024 Employee Stock Purchase Plan on May 20, 2026.
OnKure Therapeutics, Inc.’s Chief Financial Officer Jason A. Leverone reported an automatic sale of 303 shares of Class A Common Stock at a weighted average price of $4.3963 per share. The shares were sold to cover tax withholding obligations tied to vesting RSUs. After this transaction, he directly holds 18,802 shares, including 3,105 shares acquired through the 2024 Employee Stock Purchase Plan on May 20, 2026.
OnKure Therapeutics director Edward T. Mathers received a stock option grant representing 7,650 shares of Class A Common Stock. The option has an exercise price of $4.30 per share and expires on June 3, 2036. All 7,650 options will vest on the earlier of June 4, 2027 or the day before OnKure’s next annual meeting of stockholders, contingent on his continued service.
OnKure Therapeutics, Inc. director Liam Ratcliffe received a grant of stock options covering 1,275 shares of Class A common stock. The options have an exercise price of $4.3000 per share and expire on June 3, 2036. According to the vesting terms, 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the issuer's next annual meeting of stockholders, provided he continues as a service provider through the vesting date. Following this grant, he holds 1,275 derivative securities directly in this option award.
OnKure Therapeutics director Andrew John Phillips received a grant of stock options covering 7,650 shares of Class A common stock at an exercise price of $4.30 per share. The options vest 100% on the earlier of June 4, 2027 or the day before the next annual stockholder meeting, contingent on his continued service, and expire on June 3, 2036.
OnKure Therapeutics, Inc. director Valerie Malyvanh Jansen received a grant of stock options covering 7,650 shares of Class A Common Stock. The options have an exercise price of $4.30 per share and expire on June 3, 2036.
All 7,650 option shares will vest 100% on the earlier of June 4, 2027 or the day prior to OnKure’s next annual meeting of stockholders, if she continues as a service provider through that date. Following this grant, she holds 7,650 options directly.
OnKure Therapeutics director Michael G. Grey received a grant of 7,650 stock options to purchase Class A common stock at an exercise price of $4.30 per share. These options vest 100% on the earlier of June 4, 2027 or the day before the company’s next annual stockholder meeting, provided he continues as a service provider, and expire on June 3, 2036.
OnKure Therapeutics director R. Michael Carruthers received a new stock option grant. On June 4, 2026, he was granted options covering 7,650 shares of Class A common stock at an exercise price of $4.30 per share.
All 7,650 option shares will vest on the earlier of June 4, 2027 or the day before OnKure’s next annual stockholder meeting, as long as he continues as a service provider through that date. After this grant, he holds options for 7,650 shares directly, with an expiration date of June 3, 2036.
OnKure Therapeutics, Inc. reported that President and CEO Nicholas A. Saccomano received a grant of employee stock options covering 330,000 shares of Class A Common Stock. The options have an exercise price of $4.07 per share and expire on March 31, 2036.
According to the filing, Saccomano holds 330,000 options following this grant, all as direct holdings. The award vests over time, with 1/48th of the option shares vesting on May 1, 2026 and monthly thereafter, contingent on his continued service with the company.
OnKure Therapeutics, Inc. reported that Chief Financial Officer Jason A. Leverone received an employee stock option grant covering 110,000 shares of Class A common stock. The options have an exercise price of $4.07 per share and expire on March 31, 2036.
According to the vesting schedule, 1/48th of the shares subject to the option will vest on May 1, 2026 and monthly thereafter, as long as he continues as a service provider through each vesting date. Following this grant, he holds 110,000 stock options directly.
Hartley Dylan reported acquisition or exercise transactions in this Form 4 filing.
OnKure Therapeutics, Inc. reported that Chief Scientific Officer Dylan Hartley received a grant of 110,000 employee stock options to buy Class A Common Stock at $4.07 per share. These options expire on March 31, 2036 and function as equity-based compensation rather than an open-market share purchase.
According to the vesting terms, 1/48th of the options will vest on May 1, 2026 and then monthly thereafter, as long as Hartley continues as a service provider. After this grant, Hartley directly holds 110,000 options covering an equal number of Class A Common shares.
OnKure Therapeutics, Inc. Chief Medical Officer Samuel Agresta reported a compensation-related grant of 110,000 employee stock options to buy Class A Common Stock. The options carry an exercise price of $4.07 per share and expire on March 31, 2036.
According to the filing, 1/48th of the options will vest on May 1, 2026 and then monthly thereafter, as long as he continues as a service provider. Following this grant, he holds 110,000 derivative securities directly, with no open-market buying or selling reported.
OnKure Therapeutics director Liam Ratcliffe received a new stock option grant as part of compensation. The award covers 15,300 options to buy Class A common stock at an exercise price of $4.14 per share, expiring on March 30, 2036.
These options vest over time: 1/36 of the grant vests on April 30, 2026 and 1/36 on the last day of each following month, as long as he continues as a service provider. After this grant, he holds 15,300 stock options directly from this award.
OnKure Therapeutics President and CEO Nicholas A. Saccomano reported a small tax-related sale of shares. He sold 86 shares of Class A Common Stock on March 23, 2026 at a weighted average price of $4.1565 per share.
According to the disclosure, these shares were automatically sold to cover tax withholding obligations tied to the vesting of restricted stock units under the company’s 2023 RSU Equity Incentive Plan. After this transaction, he directly holds 7,333 shares of Class A Common Stock.
OnKure Therapeutics, Inc. Chief Financial Officer Jason A. Leverone reported an automatic sale of 301 shares of Class A Common Stock. The shares were sold on March 23, 2026 at a weighted average price of $4.1565 per share.
According to the disclosure, the shares were automatically sold to cover tax withholding obligations tied to the vesting of restricted stock units under OnKure’s 2023 RSU Equity Incentive Plan, rather than as a discretionary trade. Following this tax-related sale, Leverone directly holds 16,000 shares of Class A Common Stock.
Edward T. Mathers, a director of OnKure Therapeutics, Inc. (OKUR), acquired 4,125 fully vested restricted stock units (RSUs) on 09/30/2025 in lieu of a quarterly cash retainer under the company's Outside Director Compensation Policy. Each RSU converts into one share of Class A Common Stock. After the reported transaction, the reporting person beneficially owns 11,399 shares. The Form 4 was filed as a single reporting-person filing and bears a signature by an attorney-in-fact dated 10/02/2025.
Nicholas A. Saccomano, President and CEO and a director of OnKure Therapeutics, Inc. (OKUR), reported a routine transaction on 09/22/2025 in which 88 shares of Class A Common Stock were sold to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs). The sale executed in multiple trades at prices ranging from $2.60 to $2.645, producing a weighted average sale price of $2.6235. Following the transaction, the reporting person beneficially owned 3,506 shares (certain of which remain as RSUs subject to vesting conditions). The Form 4 was signed by proxy on 09/24/2025.
OnKure Therapeutics CFO Jason A. Leverone reported a routine disposition of Class A common stock to cover tax withholding tied to RSU vesting. On 09/22/2025 the reporting person sold 303 shares at a weighted average price of $2.6235, leaving beneficial ownership of 12,603 shares. The filing explains the sale was automatic under the companys 2023 RSU Equity Incentive Plan and that RSUs represent contingent rights to receive one share upon vesting. The Form 4 was submitted under power of attorney on 09/24/2025.